Acacia Pharma Group plc (“Acacia Pharma” or the “Company”), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy, announces that the US Food and Drug Administration (FDA) has approved Barhemsys (amisulpride injection) for the prevention and treatment of PONV in adult patients.